Back to Search Start Over

Computable phenotype for real-world, data-driven retrospective identification of relapse in ANCA-associated vasculitis

Authors :
Vladimir Tesar
Conor Judge
John Kelleher
Zdenka Hrušková
Raashid Ahmed Luqmani
Jennifer Scott
Peter A Merkel
Mark A Little
Niall Conlon
Louis Aslett
Arthur White
Julie Power
Matthew A Rutherford
James Ng
Kuruvilla Sebastian
Sorcha O’Brien
Sarah M Moran
Source :
RMD Open, Vol 10, Iss 2 (2024)
Publication Year :
2024
Publisher :
BMJ Publishing Group, 2024.

Abstract

Objective ANCA-associated vasculitis (AAV) is a relapsing-remitting disease, resulting in incremental tissue injury. The gold-standard relapse definition (Birmingham Vasculitis Activity Score, BVAS>0) is often missing or inaccurate in registry settings, leading to errors in ascertainment of this key outcome. We sought to create a computable phenotype (CP) to automate retrospective identification of relapse using real-world data in the research setting.Methods We studied 536 patients with AAV and >6 months follow-up recruited to the Rare Kidney Disease registry (a national longitudinal, multicentre cohort study). We followed five steps: (1) independent encounter adjudication using primary medical records to assign the ground truth, (2) selection of data elements (DEs), (3) CP development using multilevel regression modelling, (4) internal validation and (5) development of additional models to handle missingness. Cut-points were determined by maximising the F1-score. We developed a web application for CP implementation, which outputs an individualised probability of relapse.Results Development and validation datasets comprised 1209 and 377 encounters, respectively. After classifying encounters with diagnostic histopathology as relapse, we identified five key DEs; DE1: change in ANCA level, DE2: suggestive blood/urine tests, DE3: suggestive imaging, DE4: immunosuppression status, DE5: immunosuppression change. F1-score, sensitivity and specificity were 0.85 (95% CI 0.77 to 0.92), 0.89 (95% CI 0.80 to 0.99) and 0.96 (95% CI 0.93 to 0.99), respectively. Where DE5 was missing, DE2 plus either DE1/DE3 were required to match the accuracy of BVAS.Conclusions This CP accurately quantifies the individualised probability of relapse in AAV retrospectively, using objective, readily accessible registry data. This framework could be leveraged for other outcomes and relapsing diseases.

Subjects

Subjects :
Medicine

Details

Language :
English
ISSN :
20565933
Volume :
10
Issue :
2
Database :
Directory of Open Access Journals
Journal :
RMD Open
Publication Type :
Academic Journal
Accession number :
edsdoj.003a60ddf5a24e539f187924518b5db0
Document Type :
article
Full Text :
https://doi.org/10.1136/rmdopen-2023-003962